Registration Dossier

Toxicological information

Endpoint summary

Currently viewing:

Administrative data

Description of key information

No skin sensitisation study with fatty acids, C9 -13 neo, potassium salts is available, thus the skin sensitisation potential will be addressed with existing data on the individual moieties potassium and neodecanoate. Fatty acids, C9 -13 neo, potassium salts is not expected to show signs of dermal sensitisation, since the two moieties potassium and neodecanoate have not shown any skin sensitisation potential in experimental testing.

Key value for chemical safety assessment

Skin sensitisation

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed (not sensitising)
Additional information:

Fatty acids, C9 -13 neo, potassium salts is not expected to show signs of dermal sensitisation, since the two constituents potassium and neodecanoic acid have not shown any skin sensitisation potential in experimental testing. Thus, fatty acids, C9 -13 neo, potassium salts is not to be classified according to regulation (EC) 1272/2008 as skin sensitising. Further testing is not required. For further information on the toxicity of the individual constituents, please refer to the relevant sections in the IUCLID and CSR.

Respiratory sensitisation

Endpoint conclusion
Endpoint conclusion:
no study available

Justification for classification or non-classification

As the two moieties potassium and neodecanoate are not sensitising, fatty acids, C9 -13 neo, potassium salts in all probability has also no sensitising activity.

According to the criteria of REGULATION (EC) No 1272/2008 and its subsequent adaptions, fatty acids, C9 -13 neo, potassium salts does not have to be classified and has no obligatory labelling requirement for sensitization by skin contact.